VTAK
Catheter Precision, Inc.
Next earnings Aug 10, 2026 · consensus $-0.10 EPS, $2.04M rev
Last earnings +9.2% on 2026-05-18
$1.09
▼ -9.92%$1.09▼ -78.75%
over 1Y
L $0.76EODHDH $5.13
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-9.9%
1W+25.3%
1M+21.1%
3M+0.0%
YTD-45.8%
1Y-78.8%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy
Revenue grew 95.0% YoY; but unprofitable (net margin -2098.0%).
Revenue (FY2025) $819K · FY2025
Catheter Precision, Inc. shows $819K in FY2025 revenue (+95.0% YoY), a -2098.0% net margin, and -243.6% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $22.0K | $14.0K | $442K | $420K | $819K |
| Gross profit | -$1.54M | -$147K | $412K | $378K | $756K |
| Operating income | -$29.3M | -$27.0M | -$78.1M | -$11.2M | -$21.1M |
| Net income | -$25.1M | -$26.9M | -$70.6M | -$16.6M | -$17.2M |
| Diluted EPS | -$248.22 | -$25.98 | — | — | — |
| Net margin | -113954.5% | -191892.9% | -15966.5% | -3962.6% | -2098.0% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$5.92M
EV / EBITDA—
EV / Sales7.2
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-585.5%
FCF yield-283.3%
Quality & risk
ROIC (est.)-164.9%
Free cash flow-$8.31M
Total debt$3.08M
Net cash-$2.99M
Altman Z-Score-31.75 distress
Piotroski F-Score4/9
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-71.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — late filing notice (2026-05-18). Worth a closer look.
- S-1 Securities registration2026-06-22
- 8-K Material agreement2026-06-08
- 8-K Earnings results2026-05-18
- 10-Q Quarterly report2026-05-18
- NT 10-Q Late filing notice2026-05-18
- 10-K/A Restated periodic report2026-04-30
- 8-K Unregistered share sales2026-04-23
- 8-K Shareholder vote2026-04-15
- 8-K Earnings results2026-03-31
Recent filings
all on EDGAR ↗SCHEDULE 13GFiling2026-06-26open ↗S-1Filing2026-06-22open ↗8-KPeriod ending 2026-06-072026-06-08open ↗8-KPeriod ending 2026-05-182026-05-18open ↗10-QPeriod ending 2026-03-312026-05-18open ↗NT 10-QPeriod ending 2026-03-312026-05-18open ↗SCHEDULE 13G/AFiling2026-05-14open ↗10-K/APeriod ending 2025-12-312026-04-30open ↗8-KPeriod ending 2026-04-172026-04-23open ↗8-KPeriod ending 2026-04-152026-04-15open ↗8-KPeriod ending 2026-03-312026-03-31open ↗10-KPeriod ending 2025-12-312026-03-31open ↗
Frequently asked
- Is Catheter Precision, Inc. (VTAK) a buy?
- VTAK currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 95.0% YoY; but unprofitable (net margin -2098.0%).
- What is Catheter Precision, Inc.'s quality score?
- VTAK scores 51.86274509803921/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001716621, latest 10-Q filed 2026-05-18) · EODHD · as of 6/26/2026, 3:54:44 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.